Nyra Medical Names Lori Chmura as CEO

Nyra Medical, a company developing its next-gen CARLEN transcatheter mitral valve repair (TMVR) technology, has appointed Lori Chmura as its new CEO.
 
She succeeds Dr. Murali Padala, who founded the company and will transition to the role of chief scientific officer.
 
“Lori’s track record of success in leading disruptive technologies to the market positions Nyra Medical well as we advance the Nyra technology into clinical stage,” Amrinder Singh, board director and principal at Vensana Capital, told the press. “Her industry and strategic expertise, paired with her tenacity make her the ideal candidate to lead Nyra Medical.  We also acknowledge and thank Dr. Padala who built the foundation for a transformative treatment for patients with mitral regurgitation and look forward to his continued leadership at the company.”
 
Chmura has over 30 years of experience of leadership experience in the medical device industry. She held roles at Medtronic, Covidien, and Johnson & Johnson, and was most recently president and CEO at Canadian medical device company Soundbite Medical Solutions. There, she led the company through FDA clearance of a device to treat calcific occlusive cardiovascular disease using shock wave energy.
 
Before Soundbite, Chmura was CEO of Dune Medical Devices, and a member of the board of directors. She exited with a sale of the company’s business in April 2020.
 
She was also recognized by the Southeast Medical Device Association as its “Woman of the Year” in 2017 and serves on the board of directors of OpSens, a cardiology-focused firm specializing in diagnostic and treatment solutions based on proprietary optical tech.
 
“I am honored and excited to join the talented team at Nyra Medical as CEO at this pivotal moment in its journey toward developing the most innovative transcatheter solution to mitral valve regurgitation,” said Chmura. With the recent funding round as well as compelling pre-clinical data, the CARLEN device is designed to safely and effectively correct mitral regurgitation across different valve anatomies, preserving the full range of other transcatheter and surgical treatments as future options. I also look forward to collaborating with Dr. Padala, in his role as Founder and Chief Scientific Officer, as we build a world class leadership team poised to advance the company’s mission of serving the multitude of patients suffering with MR each year.”
 
According to Nyra, CARLEN TMVR preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options.